Sasaki S, Tsujisaki M, Jinnohara T, Ishida T, Sekiya M, Adachi M, Takahashi S, Hinoda Y, Imai K
First Department of Internal Medicine, Sapporo Medical University.
Jpn J Cancer Res. 1998 May;89(5):562-70. doi: 10.1111/j.1349-7006.1998.tb03298.x.
We established an anti-ErbB-2 mouse-human chimeric monoclonal antibody (MoAb), CH401, which was able to kill cancer cells overexpressing the ErbB-2 protein in vitro. The analysis of the killing mechanism indicated that MoAb CH401 might be the first anti-erbB-2 mouse-human chimeric MoAb which can induce the apoptosis of cancer cells, since morphological changes and DNA fragmentation were recognized in MoAb CH401-treated cells. The ErbB-2 receptor appears to have two opposing functions: acting as a receptor both for a growth factor and for an apoptotic factor. Our results indicate that MoAb CH401 treatment may prove to be very useful for cancer therapy.
我们制备了一种抗ErbB-2小鼠-人嵌合单克隆抗体（MoAb）CH401，它能够在体外杀死过表达ErbB-2蛋白的癌细胞。对杀伤机制的分析表明，MoAb CH401可能是首个能够诱导癌细胞凋亡的抗ErbB-2小鼠-人嵌合单克隆抗体，因为在经MoAb CH401处理的细胞中观察到了形态学变化和DNA片段化。ErbB-2受体似乎具有两种相反的功能：作为生长因子和凋亡因子的受体。我们的结果表明，MoAb CH401治疗可能对癌症治疗非常有用。
